You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):阿達木單抗注射液的上市註冊申請獲批准
格隆匯 12-07 18:35

格隆匯 12 月 7日丨復星醫藥(600196.SH)公佈,近日,公司控股子公上海復宏漢霖生物技術股份有限公司及其控股子公司研製阿達木單抗注射液(即重組抗TNFα全人單克隆抗體注射液,商品名稱:漢達遠®;以下簡稱“該新藥”)用於治療類風濕關節炎強直性脊柱炎、銀屑病上市註冊申請獲國家藥品監督管理局批准

該新藥為集團自主研發的單抗生物類似藥,主要用於類風濕關節炎、強直性脊柱炎、銀屑病的治療該新藥生產場地及設施已通過上海市藥品監督管理局的GMP符合性場檢查。

截至202010,集團現階段針對該新藥累計研發投入人民幣26410(未經審計)

該新藥此次獲上市註冊批准可以類風濕關節炎、強直性脊柱炎、銀屑病者帶來更多的治療選擇豐富了集團產品線預計該新藥本次獲上市註冊批准不會對集團現階段業績產生重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account